Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AVB-001 |
| Synonyms | |
| Therapy Description |
AVB-001 comprises polymer encapsulated epithelial cells engineered to express IL-2, which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AVB-001 | AVB 001|AVB001 | AVB-001 comprises polymer encapsulated epithelial cells engineered to express IL-2, which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05538624 | Phase Ib/II | AVB-001 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | Terminated | USA | 0 |